Edgar Filing: Lockshin Curtis - Form 4/A

Lockshin C Form 4/A											
May 03, 20											
FORI	M 4 UNITED	STATES					COMMISSIO	N OMB	3235-0287		
Check this box Washington, D.C. 20549								Number:	January 31,		
if no longer STATEMENT OF CHANCES IN BENEFICIAL OWNERSHI							WNERSHIP OF	Expires:	2005		
Subject to					RITIES		Estimated burden hou response	irs per			
Form 5 obligat	ions Section 17(nge Act of 1934, of 1935 or Secti				
may co <i>See</i> Ins 1(b).	struction			•	•	ny Act of 1					
(Print or Type	e Responses)										
1. Name and Address of Reporting Person <u>*</u> Lockshin Curtis			2. Issuer Name and Ticker or Trading Symbol RXi Pharmaceuticals Corp [RXII]			-	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle)	3. Date of Earliest Transaction				(Check all applicable)				
(Lust)	(1131) ((made)	(Month/Day/Year)				X Director 10% Owner				
	PHARMACEUTIC		04/18/2013				Officer (give title Other (specify below) below)				
	ATION, 1500 WE RIVE, SUITE 210	51									
	(Street)		4. If Am	nendment, D	ate Origina	ıl	6. Individual or	Joint/Group Fili	ng(Check		
			Filed(Month/Day/Year)				Applicable Line)				
WESTBO	ROUGH, MA 015	81	04/22/2	2013				y One Reporting Porting Portion of the Portion of t			
(City)	(State)	(Zip)	Tal	ble I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
1.Title of	2. Transaction Date			3. Transaction	4. Securit		5. Amount of	6. Ownership	7. Nature of		
Security (Instr. 3)	(Month/Day/Year)	any	Date, 11	Transactio Code	nAcquired Disposed		Securities Beneficially	Form: Direct (D) or Indirect	Indirect Beneficial		
		(Month/Da	y/Year)	(Instr. 8)	(Instr. 3, 4	4 and 5)	Owned Following	(I) (Instr. 4)	Ownership (Instr. 4)		
						(A)	Reported	(111501. 1)	(instr. i)		
						or	Transaction(s) (Instr. 3 and 4)				
				Code V	Amount	(D) Price	````				
Reminder: R	eport on a separate line	e for each cla	ass of sec	curities bene	-	-	-				
							pond to the colle ained in this forn		SEC 1474 (9-02)		
					requi	red to respo ays a curre	ond unless the fo ntly valid OMB co	rm	(* * -)		
	Tab					posed of, or convertible s	Beneficially Owner securities)	d			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: Lockshin Curtis - Form 4/A

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		/Year)	(Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Stock Option (right to buy)	\$ 0.2395	04/18/2013		A	1,000,000		(1)	04/18/2023	Common stock	1,000,0

Reporting Owners

	Relationships					
Reporting Owner Name / Addres	Director	10% Owner	Officer	Other		
Lockshin Curtis C/O RXI PHARMACEUTICALS CORF 1500 WEST PARK DRIVE, SUITE 210 WESTBOROUGH, MA 01581		Х				
Signatures						
/s/ Caitlin Kontulis, attorney-in-fact	05/03/2013					

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The award will vest in equal quarterly installments of 250,000 shares on each of July 18, 2013, October 18, 2013, January 18, 2014, and April 18, 2014.

Remarks:

This amendment is filed to correct the vesting terms of the stock option award.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.